Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote & News

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 977 5700

Website: apellis.com

Address:

100 Fifth Avenue, Waltham, United States

buylowandwait Oct. 24 at 4:43 PM

$APLS The company was valued at 90+ dollar based on GA promise. However, in the last few quarters, the GA revenue stopped growing, which triggered big sell-off along with drama from extremely rare blindness triggered by injection. If Q3, GA resumes growth, or if there is guidance of resuming growth from the management team, this will take off. Keep in mind we have C3G/IC-MPGN launch ongoing, which is an very effective drug. 100K+ shares holding !

1 · Reply

Whiskeyunderthebed Oct. 24 at 1:23 PM

$APLS next week -will it be a trick or a treat...

0 · Reply

philosophernutz Oct. 23 at 2:44 PM

$APLS a little bit of momentum....

0 · Reply

RonIsWrong Oct. 23 at 2:05 PM

$APLS 👀 I picked up some calls 3 days ago 🤷‍♂️

3 · Reply

buylowandwait Oct. 22 at 7:51 PM

$APLS 30+ Soon. Fundamentals are strong ! Scientists are running the company, not ideal, but the company assets are real. The drugs works and worths a lot more than the current valuation.

0 · Reply

philosophernutz Oct. 21 at 10:23 PM

$APLS I think the analysts already know the numbers are gonna come out better than expected, that's why we're seeing these random upgrades.

1 · Reply

Whiskeyunderthebed Oct. 21 at 7:58 PM

$APLS buying it up at the closing...come out you thieves.

0 · Reply

Jay4profit Oct. 21 at 4:05 PM

$APLS looks good!

0 · Reply

The_Fact_ster Oct. 21 at 3:55 PM

$APLS Feb 5th... the last time the stock price here was above $30/shr What a bizarre fricken year.

0 · Reply

Whiskeyunderthebed Oct. 21 at 3:34 PM

$APLS Hopefully they can run this up to $30 before the call and if we get lucky with sales numbers we could get some upgrades and move to $35. I know I'm dreamin...

1 · Reply

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Oct 16, 2025, 7:00 AM EDT - 9 days ago

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Sep 30, 2025, 4:34 PM EDT - 25 days ago

Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

Sep 9, 2025, 12:55 PM EDT - 6 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)

Sep 4, 2025, 11:20 AM EDT - 7 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 3, 2025, 11:24 AM EDT - 7 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 14, 2025, 12:12 PM EDT - 2 months ago

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Aug 2, 2025, 4:23 AM EDT - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 2:29 PM EDT - 3 months ago

Apellis Pharmaceuticals: The Picture Becomes Clearer

Jul 31, 2025, 7:05 AM EDT - 3 months ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 12:12 PM EDT - 3 months ago

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

Jul 28, 2025, 7:19 PM EDT - 3 months ago

FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Jul 24, 2025, 7:00 AM EDT - 3 months ago

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 3 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Jul 1, 2025, 7:35 AM EDT - 4 months ago

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Jul 1, 2025, 7:00 AM EDT - 4 months ago

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Jun 6, 2025, 9:15 AM EDT - 5 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:28 AM EDT - 5 months ago

Apellis Pharmaceuticals: Have Some Patience

May 7, 2025, 1:18 PM EDT - 6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 6 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 6 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 30, 2025, 7:00 AM EDT - 6 months ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 6 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 1, 2025, 2:11 PM EDT - 7 months ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Mar 5, 2025, 2:06 PM EST - 8 months ago

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:04 PM EST - 8 months ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 2, 2025, 2:08 AM EST - 8 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:05 AM EST - 8 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 8 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 2:00 AM EST - 8 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Feb 14, 2025, 7:00 AM EST - 9 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 4, 2025, 4:05 PM EST - 9 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 27, 2025, 4:00 PM EST - 9 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Jan 21, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect

Jan 20, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out

Jan 19, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 10 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 16, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation

Jan 15, 2025, 10:00 AM EST - 10 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 14, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Jan 13, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Jan 13, 2025, 9:00 AM EST - 10 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect

Jan 9, 2025, 10:00 AM EST - 10 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation

buylowandwait Oct. 24 at 4:43 PM

1 · Reply

Whiskeyunderthebed Oct. 24 at 1:23 PM

$APLS next week -will it be a trick or a treat...

0 · Reply

philosophernutz Oct. 23 at 2:44 PM

$APLS a little bit of momentum....

0 · Reply

RonIsWrong Oct. 23 at 2:05 PM

$APLS 👀 I picked up some calls 3 days ago 🤷‍♂️

3 · Reply

buylowandwait Oct. 22 at 7:51 PM

$APLS 30+ Soon. Fundamentals are strong ! Scientists are running the company, not ideal, but the company assets are real. The drugs works and worths a lot more than the current valuation.

0 · Reply

philosophernutz Oct. 21 at 10:23 PM

$APLS I think the analysts already know the numbers are gonna come out better than expected, that's why we're seeing these random upgrades.

1 · Reply

Whiskeyunderthebed Oct. 21 at 7:58 PM

$APLS buying it up at the closing...come out you thieves.

0 · Reply

Jay4profit Oct. 21 at 4:05 PM

$APLS looks good!

0 · Reply

The_Fact_ster Oct. 21 at 3:55 PM

$APLS Feb 5th... the last time the stock price here was above $30/shr What a bizarre fricken year.

0 · Reply

Whiskeyunderthebed Oct. 21 at 3:34 PM

$APLS Hopefully they can run this up to $30 before the call and if we get lucky with sales numbers we could get some upgrades and move to $35. I know I'm dreamin...

1 · Reply

philosophernutz Oct. 21 at 12:27 PM

$APLS Mofo analysts are expecting positive earnings. $1.06 a share. Let's hope APLS doesn't drop the ball again. 😭

0 · Reply

Jennifur Oct. 21 at 12:21 PM

$APLS I had a talk with Cedric and put him in his place.....

0 · Reply

monoksop Oct. 20 at 7:43 PM

$APLS Piper Sandler raised their price target from $28 to $30. It ain’t much, but it’s honest work.

0 · Reply

buylowandwait Oct. 20 at 6:02 PM

$APLS Keep in mind that the two assets are blockbuster each. With GA being a multi-billion opportunity, and C3G/IC-MPGN will hit blockbuster in a few short years. Yet, the enterprise value is less than 3B. I see minimum 5B enterprise value with the current XBI environment, which translates into 50 PPS.

1 · Reply

buylowandwait Oct. 20 at 5:58 PM

$APLS How high can this go? 30+ near term. I am actually surprised that this isn't 30 already given the strong recovery from XBI. Long with 100K+ shares, barely break even and waiting for further price appreciation. Jennifer, keep on bitching, you go girl....

1 · Reply

monoksop Oct. 20 at 4:25 PM

$APLS Almost like this is exactly what happened. Better start calling me the APLS whisperer.

2 · Reply

ThatsNoMoon Oct. 20 at 3:53 PM

$APLS LFG!

0 · Reply

4Reel Oct. 20 at 1:11 PM

$APLS yep great news again. Already got BOA to raise a price target too. 30 by end of the yr, sooner than later imo

0 · Reply

Jennifur Oct. 16 at 9:59 PM

$APLS Will probably find out at earnings that management blew the whole 300 million Sobi royalty cash on R&D

2 · Reply

Still_a_Chance Oct. 16 at 2:35 PM

$APLS break $26 and 🚀

1 · Reply

Winning_calls Oct. 16 at 2:18 PM

$APLS join our team

1 · Reply

philosophernutz Oct. 16 at 2:09 PM

$APLS Here we go, it's go time. Can we get positive earnings? https://finance.yahoo.com/news/apellis-pharmaceuticals-host-conference-call-110000268.html

1 · Reply

Market Cap	3.56B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-25.32%
Debt to Equity Ratio	2.31

Volume	1,265,500
Avg Vol	2,229,690
Day's Range	N/A - N/A
Shares Out	126.29M
Stochastic %K	84%
Beta	0.69
Analysts	Strong Sell
Price Target	$38.05